Novo Nordisk invests in new production facility in Odense

Denmark-based diabetes and obesity giant Novo Nordisk (NOV: N) says it plans to invest 8.5 billion Danish kroner ($1.2 billion) to establish a completely new production facility in Odense, Denmark.

The investment marks the first time in this century that Novo Nordisk breaks ground in Denmark by establishing a new production site. It adds to the companies list of recent investments in new production facilities, included earlier this month $420 million at its control laboratory in Hillerød, Denmark, and $4.1 billion to build a second fill and finishing manufacturing facility in Clayton, North Carolina, USA, announced in June.

The new Odense site will feature a state-of-the-art finished production facility and warehouse spanning over 40,000 m2. Designed to be modular and flexible, it will accommodate multiple product types within rare disease, such as hemophilia, both now and in the future.